Treatment continuity of MEK inhibitors and tumor trajectories after discontinuation in NF1 associated plexiform neurofibromas
Year: 2026
Type: article
Study design: Observational Study
Abstract: MEK inhibitors have improved the management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs), but post-discontinuation tumor behavior in routine practice remains unclear. We retrospectively analyzed 40 patients with NF1-associated PNs treated with selumetinib or luvometinib. Patients were classified as discontinuation or no discontinuation according to treatment continuity during follow-up. Outcomes were assessed using a harmonized T0/T1/T2 framework. Pain was evaluated using the Numeric Rating Scale (NRS), and longitudinal tumor change was measured in the same predefined target lesion. Nineteen patients discontinued treatment and 21 remained on treatment. The discontinuation group was older than the no-discontinuation group (median age, 24 vs. 12 years; P = 0.0002). The median T1-to-T2 interval tumor volume change was + 7.0% in the discontinuation group and − 3.0% in the no-discontinuation group ( P < 0.0001). Within the discontinuation group, median tumor volume change shifted from − 5.0% at T1 to + 5.0% at T2 ( P = 0.0003). After adjustment for age, discontinuation was associated with a 12.27-percentage-point higher T1-to-T2 interval tumor volume change (95% CI, 6.94 to 17.60; P < 0.001); the association remained present after additional adjustment for the actual T1-to-T2 interval duration (10.83% points; 95% CI, 3.15 to 18.52; P = 0.006). Pain outcomes were more heterogeneous, with no significant between-group difference in T1-to-T2 NRS change. Cost-related interruption was the most frequent documented reason for discontinuation (10/19, 52.6%). Treatment discontinuation was associated with less favorable tumor trajectories in this real-world NF1-PN cohort. However, substantial age imbalance, limited age overlap, heterogeneous observation intervals, and the retrospective observational design preclude causal inference. Cost-related interruption was the most frequent documented reason for discontinuation and may represent an important practical barrier to sustained MEK inhibitor therapy.
Source: Discover Oncology
Authors: Lei Zhang, Kai Wang, Lei Cheng, Zhenlei Liu, Hao Wu
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7160865177
